来自All of Us研究项目的研究人员通过分析31,669例接受CYP2D6代谢型阿片类药物（氢可酮、曲马多、可待因、羟考酮）治疗的患者数据，发现CYP2D6中间代谢型 (pIM)和弱代谢型 (pPM)患者因疼痛就诊急诊科的风险显著高于正常代谢型 (pNM)和超快代谢型 (pUM)（加权OR=1.19）。研究提示整合CYP2D6基因型和药物相互 ...

值得注意的是，成人CYP2D6超快代谢型（UM）和弱代谢型（PM）患者换药风险较正常代谢型（NM）显著增加2-3倍（OR=2.9和2.3），提示相对代谢比例可能比绝对浓度更能预测临床转归。 该成果为SSRI个体化用药提供了重要循证依据。

The cytochrome p450 enzyme, CYP2D6, metabolises approximately 20% of marketed drugs. CYP2D6 multiple variants are associated with altered enzyme activities. Genotyping 1018 Caucasians for CYP2D6 ...

Commercial tests for CYP2D6 genotyping are available, and some experts have argued that they should be used in clinical practice, particularly in the case of postmenopausal women, where there is ...

Of the 3 beta-blockers recommended for use in HF patients, 2 are metabolized by CYP2D6, “a highly polymorphic enzyme of the P450 family.” Because of this, these agents are subject to varying ...

Concomitant strong CYP3A4 or CYP2D6 inhibitors, or CYP2D6 poor metabolizer: reduce aripiprazole dose by ½. Concomitant strong CYP3A4 inducers: double aripiprazole dose (max 30mg/day) over 1–2 ...